WallStSmart

Edwards Lifesciences Corp (EW)vsNano X Imaging Ltd (NNOX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 49222% more annual revenue ($6.07B vs $12.30M). EW leads profitability with a 17.7% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

NNOX

Avoid

28

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 8.0
Piotroski: 3/9Altman Z: 2.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Intrinsic value data unavailable for NNOX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

NNOX2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

NNOX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$169.80M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : NNOX

The strongest argument for NNOX centers on Price/Book, Debt/Equity. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Bear Case : NNOX

The primary concerns for NNOX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

EW profiles as a mature stock while NNOX is a value play — different risk/reward profiles.

NNOX carries more volatility with a beta of 1.41 — expect wider price swings.

NNOX is growing revenue faster at 13.7% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 28/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Nano X Imaging Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Nano-X Imaging Ltd., a development-stage company, develops, produces and markets digital X-ray source technology for the medical imaging industry globally. The company is headquartered in Neve Ilan, Israel.

Visit Website →

Want to dig deeper into these stocks?